Please ensure Javascript is enabled for purposes of website accessibility
Patrick Bafuma

Patrick Bafuma


Recent articles


3 Last-Minute Healthcare Stocking Stuffers

Here are three stocks sure to pique the interest of that special someone.


10x Genomics Stock: Bull vs. Bear

After a hot start, the stock has recently lagged the market. Is now a good time to buy?


Better Buy: Ocugen or Novavax?

Will either of these hopeful vaccine makers continue to thrash the market?


Better Buy: Bristol Myers Squibb vs. Merck

Which pharma giant is right for you?


Pfizer: Bull vs. Bear

The pharmaceutical giant has lagged the market over the past decade, but will the fight against COVID-19 change that?


Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.


Binge Watching Dopesick? Here Are 3 Stocks That Involve an Opioid-Free Recovery

Check out these companies utilizing non-pharmaceutical means to optimize America's health.


Should Biogen Investors Be Preparing for the Worst?

With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?


Was Atea Pharmaceutical's Flop Predictable?

Were warning signs there for investors all along?


Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

Codexis is leveraging its core technology to create more effective life science tools.


Is This Beaten Down Biotech a Bad News Buy?

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?


2 Tricks and a Treat for Gene Therapy Investors

It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.


Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?

This partnership is showing early efficacy in the race for an oral COVID-19 treatment, but Atea and Roche are on their haunches.


This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?

Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.


Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar

Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.


This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money

An effective oral antiviral therapy for the coronavirus may be around the corner.


Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.


This Under-the-Radar Dementia Treatment Could Reward Investors

Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.


2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't

After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.


Could This Recently IPOed Medical Device Maker Make You Rich?

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.